Immune co-signaling to treat cancer Chapter uri icon

Overview

MeSH Major

  • Antibodies
  • CTLA-4 Antigen
  • Immunotherapy
  • Neoplasms
  • Programmed Cell Death 1 Receptor

abstract

  • © 2013 Springer Science+Business Media New York. All rights are reserved.The past two decades have been marked by a growing understanding of the co-stimulatory and co-inhibitory pathways that are critical to the generation of an effective, well-regulated immune response. Capitalizing on an increasingly nuanced appreciation for the role that these molecules play in anti-tumor immune responses, a diversity of novel therapies to treat human cancers are being explored. The ground-breaking success of anti-CTLA-4 therapy in the treatment of advanced melanoma has set the stage for the clinical development of agents targeting a diversity of co-stimulatory and co-inhibitory molecules. Herein, we review the co-signaling molecules that regulate T cell activation with a focus on their potential role(s) in anti-tumor immune responses. Where available, pre-clinical and clinical studies evaluating the anti-tumor activity of agents targeting these molecules are presented.

publication date

  • May 2013

Research

keywords

  • Book Chapter

Identity

Digital Object Identifier (DOI)

  • 10.1007/978-1-4614-4732-0_8

Additional Document Info

start page

  • 211

end page

  • 280

volume

  • 9781461447320